Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.43 |
| ▸ | LIPC | P11150 | 1/20 | 0.43 |
| ▸ | ACACB | O00763 | 13/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.42 |
| ▸ | MTOR | P42345 | 2/20 | 0.42 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17767822 | 0.91 | ACACB (0.44) | FFAR1LIPGLIPCACACBPIK3CA | |
| SCHEMBL17772960 | 0.91 | POLB (0.46) | FFAR1PIK3CAMTORPIK3CGSCN9A | |
| SCHEMBL17772963 | 0.91 | FFAR1 (0.43) | FFAR1LIPGLIPCACACBPIK3CA | |
| SCHEMBL17773010 | 0.91 | PIK3CA (0.42) | FFAR1LIPGLIPCACACBPIK3CA | |
| SCHEMBL17772973 | 0.87 | SCD (0.44) | PIK3CAPIK3CGSCN9A | |
| SCHEMBL17767837 | 0.86 | PIK3CA (0.42) | FFAR1LIPGLIPCACACBPIK3CA | |
| SCHEMBL17767833 | 0.83 | LMNA (0.48) | ACACB | |
| SCHEMBL17772966 | 0.82 | POLB (0.43) | FFAR1ACACBPIK3CAPIK3CGSCN9A | |
| SCHEMBL28484261 | 0.82 | LIPG (0.37) | FFAR1LIPGLIPCSCN9A | |
| SCHEMBL17773015 | 0.82 | LMNA (0.44) | FFAR1PIK3CAMTORPIK3CGSCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107428730-B | 1,3, 5-triazinyl PI3K inhibitors as anti-cancer agents and methods of making the same | 科学与工业研究会 | 2020-10-16 | — | — | CN | claimed |
| EP-3221307-B1 | NOVEL 1,3,5 -TRIAZINE BASED PI3K INHIBITORS AS ANTICANCER AGENTS AND A PROCESS FOR THE PREPARATION THEREOF | COUNCIL SCIENT IND RES (IN) | 2019-07-24 | — | — | EP | claimed |
| US-9951040-B2 | 1,3,5 -triazine based PI3K inhibitors as anticancer agents and a process for the preparation thereof | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2018-04-24 | — | — | US | claimed |
| US-20170342049-A1 | NOVEL 1,3,5 -TRIAZINE BASED PI3K INHIBITORS AS ANTICANCER AGENTS AND A PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2017-11-30 | — | — | US | claimed |
| CN-107428730-B | 1,3, 5-triazinyl PI3K inhibitors as anti-cancer agents and methods of making the same | 科学与工业研究会 | 2020-10-16 | — | — | CN | disclosed |
| EP-3221307-B1 | NOVEL 1,3,5 -TRIAZINE BASED PI3K INHIBITORS AS ANTICANCER AGENTS AND A PROCESS FOR THE PREPARATION THEREOF | COUNCIL SCIENT IND RES (IN) | 2019-07-24 | — | — | EP | disclosed |
| EP-3221307-B1 | NOVEL 1,3,5 -TRIAZINE BASED PI3K INHIBITORS AS ANTICANCER AGENTS AND A PROCESS FOR THE PREPARATION THEREOF | COUNCIL SCIENT IND RES (IN) | 2019-07-24 | — | — | EP | disclosed |
| US-9951040-B2 | 1,3,5 -triazine based PI3K inhibitors as anticancer agents and a process for the preparation thereof | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2018-04-24 | — | — | US | disclosed |
| US-9951040-B2 | 1,3,5 -triazine based PI3K inhibitors as anticancer agents and a process for the preparation thereof | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2018-04-24 | — | — | US | disclosed |
| US-20170342049-A1 | NOVEL 1,3,5 -TRIAZINE BASED PI3K INHIBITORS AS ANTICANCER AGENTS AND A PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2017-11-30 | — | — | US | disclosed |
| US-20170342049-A1 | NOVEL 1,3,5 -TRIAZINE BASED PI3K INHIBITORS AS ANTICANCER AGENTS AND A PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170342049-A1 | NOVEL 1,3,5 -TRIAZINE BASED PI3K INHIBITORS AS ANTICANCER AGENTS AND A PROCESS FOR THE PREPARATION THEREOF | PIK3CA, PIK3R5, PIK3CD | FFAR1 2474/4885LIPG 4094/4885LIPC 2231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.